Subscribe
gutzemberg
gutzemberg / iStockphoto.com
25 October 2017Americas

Sanofi takes on Mylan over diabetes injection

Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sanofi sues Merck over Lantus patents
21 September 2016   Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus and Lantus SoloSTAR.
Americas
Sanofi sues Eli Lilly to halt Lantus biosimilar
10 July 2014   French pharmaceutical company Sanofi has sued Eli Lilly for infringing seven patents that cover its blockbuster diabetes drug Lantus (insulin glargine).
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Sanofi sues Merck over Lantus patents
21 September 2016   Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus and Lantus SoloSTAR.
Americas
Sanofi sues Eli Lilly to halt Lantus biosimilar
10 July 2014   French pharmaceutical company Sanofi has sued Eli Lilly for infringing seven patents that cover its blockbuster diabetes drug Lantus (insulin glargine).
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

More on this story

Americas
Sanofi sues Merck over Lantus patents
21 September 2016   Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus and Lantus SoloSTAR.
Americas
Sanofi sues Eli Lilly to halt Lantus biosimilar
10 July 2014   French pharmaceutical company Sanofi has sued Eli Lilly for infringing seven patents that cover its blockbuster diabetes drug Lantus (insulin glargine).
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers